← Back to Patent Explorer
US4529594A Expired / Lapsed US ⏱️ 0.0 years remaining

Protein having antitumor activity

Assignee: Asahi Kasei Corp
•
Filing: 1984-07-11
•
Granted: 1985-07-16
•
Expires: 2004-07-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A protein having a polypeptide subunit containing an N-terminal amino acid sequence of Ser-Ala-Ser-Arg-Ala-Leu-Ser-Asp-Lys-Pro-Leu-Ala-His-Val-Val-Ala-Asn-Pr o-Gln-Val-Glu-Gly-Gln-Leu-Gln-Trp-Leu. The protein of the present invention is obtained in substantially pure form at high activity recovery, and is excellent in inducing necrosis of tumors with no toxicity upon the normal tissues of the living body. The protein of the present invention is thermally stable and, therefore, when preparation of pharmaceutical compositions is conducted, the protein of the present invention can be stably formulated into compositions.

Inventors

  • 👤 Hiroshi Hayashi
  • 👤 Junji Kuwashima

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 19:15
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; A; A61; A61P; A61P35/00; C07K14/52; C07K14/525; Y; Y10; Y10S; Y10S530/00; Y10S530/82; Y10S530/825; Y10S530/827; Y10S530/828; Y10S530/829; Y10S530/83

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 152 words
A protein having an antitumor activity comprising a polypeptide subunit having an N-terminal amino acid sequence of the following formula (I): Ser-Ala-Ser-Arg-Ala-Leu-Ser-Asp-Lys-Pro-Leu-Ala-His-Val-Val-Ala-Asn-Pro-Gln-Val-Glu-Gly-Gln-Leu-Gln-Trp-Leu- wherein Ala stands for alanine residue, Arg an arginine residue, Asn an asparagine residue, Asp an aspartic acid residue, Gln a glutamine residue, Glu a glutamic acid residue, Gly a glycine residue, His a histidine residue, Leu a leucine residue, Lys a lysine residue, Pro a proline residue, Ser a serine residue, Trp a tryptophan residue and Val a valine residue; and which protein has: (a) a molecular weight of 40,000±5,000 in terms of a value as measured by a gel filtration method as defined herein and a molecular weight of 17,500±2,000 in terms of a value as measured by an SDS-polyacrylamide gel electrophoresis method as defined herein; and (b) an isoelectric point of 5.0±0.3 in terms of a value as measured by an isoelectric focusing method as defined herein.
Claim 2
Dependent Claim 152 words
A protein having an antitumor activity comprising a polypeptide subunit having an N-terminal amino acid sequence of the following formula (I): Ser-Ala-Ser-Arg-Ala-Leu-Ser-Asp-Lys-Pro-Leu-Ala-His-Val-Val-Ala-Asn-Pro-Gln-Val-Glu-Gly-Gln-Leu-Gln-Trp-Leu- wherein Ala stands for alanine residue, Arg an arginine residue, Asn an asparagine residue, Asp an aspartic acid residue, Gln a glutamine residue, Glu a glutamic acid residue, Gly a glycine residue, His a histidine residue, Leu a leucine residue, Lys a lysine residue, Pro a proline residue, Ser a serine residue, Trp a tryptophan residue and Val a valine residue; and which protein has: (a) a molecular weight of 40,000±5,000 in terms of a value as measured by a gel filtration method as defined herein and a molecular weight of 17,500±2,000 in terms of a value as measured by an SDS-polyacrylamide gel electrophoresis method as defined herein; and (b) an isoelectric point of 5.0±0.3 in terms of a value as measured by an isoelectric focusing method as defined herein.
Claim 3
Dependent Claim 23 words
A substantially pure protein having an antitumor activity comprising the polypeptide subunit having the N-terminal amino acid sequence as defined in claim 1.
Claim 4
Dependent Claim 24 words
A pharmaceutical composition comprising an effective antitumor amount of a protein of claim 1 and at least one pharmaceutically acceptable carrier, diluent or excipient.
Claim 5
Dependent Claim 24 words
A pharmaceutical composition comprising an effective antitumor amount of a protein of claim 2 and at least one pharmaceutically acceptable carrier, diluent or excipient.
Claim 6
Dependent Claim 20 words
A method for treating tumors by administering to a host an effective antitumor amount of a protein of claim 1.

References Cited (Backward Citations)

US4076701A Cited
US4457863A Cited
US4309418A Cited
US4405608A Cited
EP0090892A1 Cited
US4447355A Cited
US4390468A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-07-15 1989-01-14 1989-07-16 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-07-15 1993-01-14 1993-07-16 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-07-15 1997-01-14 1997-07-16 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag